Price
No data yet.
Social Signal Score
Revenue
$12.2K-85.98%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark White
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 8
- Beta
- 4.04
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -52.73
Financials
Revenue
$12.2K-86.0%Net Income
$-2.24MEBITDA
$-2.24MFree Cash Flow
$-1.80MEPS (diluted)
$-0.11Shares Outstanding (diluted)
21.14M-67.9%Operating Expenses
$1.35MCash & Debt
$1.00MRevenue by Segment (annual)
$301.6KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $301.6K | $-8.22M | $-0.50 |
| 2024 | $168.7K | $-7.61M | $-0.83 |
| 2023 | $110.7K | $-4.65M | $-0.63 |
| 2022 | $1.32M | $-1.70M | $-0.23 |
| 2021 | $144.1K | $-6.08M | $-0.83 |
| 2020 | $242.9K | $-3.40M | $-0.47 |
| 2019 | $207.4K | $-5.02M | $-0.69 |
Valuation
NXLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Neutral
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study Further analysis of ADAS-Cog data from the Company's randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer's Disease and in Radiology — identifies specific improvemen
View source ↗ - Newsglobenewswire.com·7d ago·Neutral
Nexalin Technology Announces Reverse Stock Split HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split rat…
View source ↗
Earnings
Wed, Dec 2(in 3 months)
Consensus estimate $-0.09 per share
Typical surprise -8.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.11 vs $-0.10miss
- Fri, May 8$-0.11 vs $-0.11beat
- Wed, Mar 25$-0.13 vs $-0.12miss
- Fri, Nov 14$-0.13 vs $-0.12miss
- Wed, Aug 6$-0.10 vs $-0.10beat
- Tue, May 13$-0.15 vs $-0.10miss
Estimates and results for NXL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NXL officers and directors.
- Bought
- $1.4m
- Sold
- $96k
29 trades
1 trade
- Elson Marilynsold
- Shelton Carolyn Hambybought
- Owens Davidbought
- Owens Davidbought
- Owens Davidbought
- Owens Davidbought
- Owens Davidbought
- Kazden Alanbought
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.